The efficacy and safety of ivabradine hydrochloride in hemodialysis patients with chronic heart failure

Abstract

AbstractIntroductionThere is little evidence for ivabradine hydrochloride in patients undergoing hemodialysis.MethodsIn this open‐label prospective interventional trial of hemodialysis patients with chronic heart failure, during 12 weeks of treatment, changes in Heart rate (HR), frequency of dialysis‐related hypotension were examined, and we investigated health‐related quality of life (HR‐QOL) and adverse effects.Results18 patients from 6 facilities were enrolled in the study. HR significantly decreased over time, from 87 ± 12.61/min at baseline to 75.85 ± 8.91/min (p = 0.0003), and systolic blood pressure also increased significantly (p < 0.0001). The frequency of dialysis‐related hypotension was markedly reduced (p = 0.0001). The HR‐QOL survey showed significant improvements in Social Functioning among others (p = 0.0178). No specific adverse events occurred.ConclusionIvabradine hydrochloride improved dialysis‐related hypotension. Furthermore, the HR‐QOL improvement effect were suggested. These results demonstrated the safety and effectiveness of ivabradine hydrochloride.